Phenobarbital is drug used in neonates treated for seizures and hypoxic-ischemic encephalopathy with whole body hypothermia or without hypothermia. Pharmacokinetics (PK) and pharmacodynamics (PD) and dosage of phenobarbital are not understood very well yet in neonates with multiorgan dysfunction syndrome undergoing hypothermia respectively.
Analysis of PK/PD and covariates of PK/PD of phenobarbital might lead to optimize dosage regimen of phenobarbital to prevent insufficient and toxic drug effects in this population